Analysts Offer Predictions for Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Research analysts at Northland Securities issued their Q1 2026 EPS estimates for Brainsway in a report released on Thursday, January 22nd. Northland Securities analyst C. Byrnes expects that the company will post earnings of $0.08 per share for the quarter. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q2 2026 earnings at $0.12 EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.64 EPS.

BWAY has been the topic of a number of other research reports. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright boosted their price objective on Brainsway from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Brainsway currently has an average rating of “Moderate Buy” and a consensus target price of $27.00.

Brainsway Trading Down 4.8%

Shares of NASDAQ BWAY opened at $23.04 on Friday. The stock has a fifty day simple moving average of $18.88 and a two-hundred day simple moving average of $16.09. Brainsway has a 1-year low of $7.84 and a 1-year high of $24.84. The firm has a market cap of $451.12 million, a price-to-earnings ratio of 76.80 and a beta of 1.19.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.03). The company had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in shares of Brainsway during the second quarter valued at about $85,000. Bank of America Corp DE bought a new position in shares of Brainsway in the third quarter valued at approximately $107,000. Centiva Capital LP purchased a new position in Brainsway during the third quarter valued at approximately $181,000. Palumbo Wealth Management LLC increased its holdings in Brainsway by 37.9% during the 4th quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock worth $310,000 after acquiring an additional 4,483 shares during the period. Finally, Y.D. More Investments Ltd bought a new stake in Brainsway during the 3rd quarter worth approximately $263,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.